Current status of ovarian cancer

Simple item page
dc.contributor.authorR Buhachaten_US
dc.date.accessioned2011-02-22T06:20:07Z
dc.date.available2011-02-22T06:20:07Z
dc.date.created2010-01-15en_US
dc.date.issued2010-01-15en_US
dc.description.abstractAbout 1,600 cases of ovarian cancer are diagnosed each year in Thailand. Advanced stage is the presenting symptom. The overall 5-year survival is 26%. Nearly 5-10% of ovarian cancer cases are hereditary that need professional genetic counseling. In high risk families genetic testing is required. CA125 and transvaginal ultrasonography are the screening methods for this malignancy in the general population that are currently being investigated in the UKCTOCS research. The stage and extension of disease are the predictable outcome after treatment. The most useful management is optimal cytoreductive surgical staging especially conducted by trained gynecologic oncologist. Platinum and paclitaxel is the main chemotherapeutic agent in adjuvant modality for high risk ovarian cancer. On-going research for better survival result in the treatment of ovarian cancer includes less radical surgery to preserve fertility function, neoadjuvant chemotherapy followed by interval debulking and intra-peritoneal chemotherapy.en_US
dc.identifier.citationSongklanagarind Medical Journal; Vol. 25 No. 6 Nov-Dec 2007; 537-547en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/132176
dc.language.isoen_USen_US
dc.publisherSongklanagarind Medical Journalen_US
dc.rightsFaculty of Medicine, Prince of Songkla University, Songkla, Thailanden_US
dc.source.urihttps://thailand.digitaljournals.org/index.php/SOMJ/issue/archiveen_US
dc.source.urihttps://thailand.digitaljournals.org/index.php/SOMJ/article/view/980en_US
dc.titleCurrent status of ovarian canceren_US
dc.typeReview Articleen_US
Files
Collections
Songklanagarind Medical Journal